TSE:MDNA Medicenna Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. C$1.48 -0.08 (-5.13%) (As of 06/30/2022 12:00 AM ET) Add Compare Share Today's RangeC$1.48▼C$1.5650-Day RangeC$0.99▼C$1.6752-Week RangeC$0.98▼C$3.82Volume17,500 shsAverage Volume29,977 shsMarket CapitalizationC$83.33 millionP/E RatioN/ADividend YieldN/APrice TargetC$8.50 ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesSocial Media Medicenna Therapeutics Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside474.3% UpsideC$8.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.55 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMedicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$8.50, Medicenna Therapeutics has a forecasted upside of 474.3% from its current price of C$1.48.Amount of Analyst CoverageMedicenna Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for MDNA. Previous Next 0.0 Dividend Strength Dividend YieldMedicenna Therapeutics does not currently pay a dividend.Dividend GrowthMedicenna Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDNA. Previous Next 2.5 News and Social Media Coverage News SentimentMedicenna Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.Search Interest2 people have searched for MDNA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicenna Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicenna Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedicenna Therapeutics has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Medicenna Therapeutics (TSE:MDNA)Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.Read More MDNA Stock News HeadlinesJune 25, 2022 | americanbankingnews.comMedicenna Therapeutics (TSE:MDNA) Rating Reiterated by HC WainwrightJune 9, 2022 | finance.yahoo.comMedicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. PatentMay 10, 2022 | finance.yahoo.comWill Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?May 3, 2022 | seekingalpha.comCIG, GRTX and MDNA among pre market gainersApril 27, 2022 | msn.comMDNA: AACR Presentations Highlight Preclinical Data for Anti-PD1-IL-2 BiSKIT and IL-13 Super-Antagonist…March 9, 2022 | finance.yahoo.comMedicenna Announces Upcoming Poster Presentations at the AACR Annual MeetingMarch 3, 2022 | finance.yahoo.comMedicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic AdvisorNovember 4, 2021 | finance.yahoo.comMedicenna Therapeutics to Announce Second Quarter 2022 Financial Results and Operational Highlights on Friday, November 12, 2021October 27, 2021 | msn.comBRIEF-Medicenna Announces FDA Clearance Of Ind To Expand The Phase 1/2 Ability Study Of Mdna11 To The United StatesOctober 27, 2021 | finance.yahoo.comMedicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United StatesJuly 20, 2021 | finance.yahoo.comWe Think Medicenna Therapeutics (TSE:MDNA) Can Afford To Drive Business GrowthJune 2, 2021 | finance.yahoo.comMDNA: Phase 1 Trial of MDNA11 to Initiate in 3Q21…May 7, 2021 | finance.yahoo.comMedicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent GlioblastomaApril 14, 2021 | finance.yahoo.comMedicenna to Present at the Bloom Burton & Co. Healthcare Investor ConferenceJanuary 10, 2021 | realmoney.thestreet.comMedicenna Therapeutics Corp. (MDNA)December 18, 2020 | msn.comWhy Sonoma, Medicenna And Dare Bioscience Are Trading Higher TodayDecember 4, 2020 | finance.yahoo.comCompanies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In GrowthOctober 30, 2020 | businesswire.comMedidata Synthetic Control Arm® Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent ...October 15, 2020 | markets.businessinsider.comMedicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)August 20, 2020 | finance.yahoo.comMedicenna to Commence Trading on NasdaqAugust 16, 2020 | ca.finance.yahoo.comMedicenna Therapeutics Corp. (MDNAF)August 7, 2020 | finance.yahoo.comMDNAF: End of Phase 2’ Meeting for MDNA55 in September 2020…August 4, 2020 | finance.yahoo.comMedicenna Reports First Quarter Fiscal 2021 Financial Results and Operational HighlightsJune 11, 2020 | finance.yahoo.comMedicenna to Present at Raymond James Human Healthcare Innovation ConferenceJune 7, 2020 | finance.yahoo.comAre Insiders Buying Medicenna Therapeutics Corp. (TSE:MDNA) Stock?See More Headlines Industry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:MDNA CUSIPN/A CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees13Year FoundedN/ACompany Calendar Today7/02/2022Next Earnings (Estimated)8/11/2022Price Target and Rating Average Stock Price ForecastC$8.50 High Stock Price ForecastC$14.00 Low Stock Price ForecastC$4.00 Forecasted Upside/Downside+474.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.06 Current Ratio11.07 Quick Ratio10.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.42 per share Price / Cash Flow3.56 Book ValueC$0.43 per share Price / Book3.47Miscellaneous Outstanding Shares56,304,000Free FloatN/AMarket CapC$83.33 million OptionableNot Optionable BetaN/A Medicenna Therapeutics Frequently Asked Questions Should I buy or sell Medicenna Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medicenna Therapeutics stock. View analyst ratings for Medicenna Therapeutics or view top-rated stocks. What is Medicenna Therapeutics' stock price forecast for 2022? 4 analysts have issued twelve-month target prices for Medicenna Therapeutics' shares. Their MDNA stock forecasts range from C$4.00 to C$14.00. On average, they anticipate Medicenna Therapeutics' share price to reach C$8.50 in the next year. This suggests a possible upside of 474.3% from the stock's current price. View analysts' price targets for Medicenna Therapeutics or view top-rated stocks among Wall Street analysts. How has Medicenna Therapeutics' stock price performed in 2022? Medicenna Therapeutics' stock was trading at C$2.10 on January 1st, 2022. Since then, MDNA stock has decreased by 29.5% and is now trading at C$1.48. View the best growth stocks for 2022 here. When is Medicenna Therapeutics' next earnings date? Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Medicenna Therapeutics. Who are Medicenna Therapeutics' key executives? Medicenna Therapeutics' management team includes the following people: Dr. Fahar Merchant Ph.D., Founder, Chairman, CEO & Pres (Age 65, Pay $569.38k)Ms. Rosemina Merchant B.Sc., M.E.Sc, Founder, Chief Devel. Officer & Director (Age 65, Pay $465.77k)Ms. Elizabeth Williams C.A., CPA, CA, CPA, CFO & Corp. Sec. (Age 44, Pay $360.88k)Dr. Martin Bexon M.D., MBBS, Acting Chief Medical Officer & Head of Clinical Devel.Dr. Samuel R. Denmeade M.D., Scientific Advisor Who are some of Medicenna Therapeutics' key competitors? Some companies that are related to Medicenna Therapeutics include ProMetic Life Sciences (PLI), Horizon Discovery Group plc (HZD.L) (HZD), Precigen (PGEN), Theratechnologies (TH), VIVO Cannabis (ABCN), Emblem (EMC), Inventiva (IVA), Verona Pharma plc (VRP.L) (VRP), VectivBio (VECT), Fennec Pharmaceuticals (FRX), Redx Pharma (REDX), Bioventix (BVXP), BriaCell Therapeutics (BCT), Agronomics (ANIC) and Arix Bioscience (ARIX). View all of MDNA's competitors. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), (ATE), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO). What is Medicenna Therapeutics' stock symbol? Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA." How do I buy shares of Medicenna Therapeutics? Shares of MDNA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Medicenna Therapeutics' stock price today? One share of MDNA stock can currently be purchased for approximately C$1.48. How much money does Medicenna Therapeutics make? Medicenna Therapeutics (TSE:MDNA) has a market capitalization of C$83.33 million. How many employees does Medicenna Therapeutics have? Medicenna Therapeutics employs 13 workers across the globe. How can I contact Medicenna Therapeutics? Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The official website for Medicenna Therapeutics is www.medicenna.com. The company can be reached via phone at +1-403-6807898. This page (TSE:MDNA) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here